Research Output Journal of Public Health and Medicine 4(2):38-42, 2024

ROJPHM

ISSN ONLINE: 1115-9715
ISSN PRINT: 1115-6147

https://rojournals.org/roj-public-health-and-medicine/

https://doi.org/10.59298/ROJPHM/2024/423842

Nanotechnology in Cancer Treatment: Targeted Drug Delivery

Winniefred Nankya

Faculty of Pharmacy Kampala International University Uganda

Email: winniefred.nankya@studwc.kiu.ac.ug

ABSTRACT

Nanotechnology is a rapidly expanding field with profound applications in medicine, particularly in targeted cancer therapy. This study examines the role of nanoparticles in enhancing drug delivery systems for cancer treatment, focusing on improving specificity and reducing toxicity to healthy tissues. By utilizing the unique properties of nanoparticles, such as liposomes, dendrimers, and polymeric nanoparticles, targeted drug delivery can effectively concentrate therapeutic agents within tumors while minimizing systemic exposure. This approach leverages both passive and active targeting mechanisms to improve drug efficacy, which is further refined by controlled release strategies. Current clinical applications and recent advancements underscore the transformative potential of nanomedicine, yet challenges related to production scalability, long-term biocompatibility, and ethical considerations require careful attention. This paper provides an overview of existing and potential nanoparticle formulations for cancer treatment, highlighting the clinical and future implications of nanotechnology in oncology.

Keywords: Nanotechnology, Cancer Treatment, Targeted Drug Delivery, Nanoparticles, Tumor Targeting.

INTRODUCTION

Nanotechnology has been a burgeoning scientific field over the last decade, with researchers using molecular building blocks as new platforms for research on potential applications in drug delivery, imaging, and tissue engineering. Consequently, the exploration of new and innovative ways to combat the chances of developing cancer through the enhancement of cancer treatment has emerged in the demonstration of nanotechnology in drug delivery, which has the potential to transform cancer therapy altogether. Due to their significant size and surface properties, nanoscale materials are suitable for various medical applications, particularly in targeted drug delivery and triggered release. With cancer being one of the leading causes of death globally, there has been a need for some form of therapeutic solution. Over the years, treatment has mainly included surgery, radiation therapy, and chemotherapy, with immunotherapies and targeted therapies growing in interest. However, while these treatments have substantially extended the lives of some people, improved progression-free survival, or achieved remission, they can also cause side effects including nausea, hair loss, a weakened immune system, and many more. As more scientific breakthroughs occur in drug development, a more holistic approach to drug delivery is an attractive field that has the power to revolutionize the meaning of improving patient quality of life. We discuss therapeutic and diagnostic nanoparticles and lay the basics of how nanomaterials could aid in cancer therapy, specifically in targeted drug delivery [1, 2].

Principles of Targeted Drug Delivery

The fundamental idea behind targeted drug delivery systems used in cancer therapy is to deliver a more substantial amount of a therapeutic agent to the tumor and reduce toxicity to healthy tissues. Specific agents that kill cancer cells directly are called chemotherapeutics, and the process of killing cancer cells using mainly chemotherapeutics is called chemotherapy. The general principles of drug targeting in

cancer involve the notion of the 'enhanced permeability and retention' (EPR) effect, which allows the design of passive drug carriers accumulated in the tumor [3, 4]. The strategic goal of targeting is to increase the effectiveness of the drug action by directing the highest possible concentration of the active substance directly to those cells that are its target. The realization that not only the actual drug, but also its carrier can be used as a targeting element of the drug delivery system was the beginning of the development of nanotechnology, including nanomedicine. Targeting can use two basic mechanisms: passive and active. Passive targeting does not involve the use of any specific drugs, and there are no artificial changes made to the drug molecules or their carriers. Passive targeting drug carriers accumulate in the target organ or tissue of the body by the nature of the conditions of the microenvironment in this organ, such as blood flow, temperature, redox conditions, pH, cellulose porosity, etc. Passive carriers aim to increase the level of the drug in the target tissue to more than 20–30% local concentration. Active targeting uses targeting elements such as ligands or monoclonal antibodies attached to a drug carrier, interacting with the specific receptors on the cancerous cell surface. Targeting molecules increase the selectivity of the drug concentration by promoting drug absorption by tumor cells. The drug carrier is specifically directed to the target tumor cell by active components binding. This is based on EPR, passive and active drug carriers which increase the concentration of the drug. In turn, it enhances therapeutic effects. The second aspect of effective cancer therapy is a controlled release of the delivered drug. More effective concentration of the drug is recommended within the tumor than in the healthy organ [5, 6].

Nanoparticle Formulations for Targeted Drug Delivery

Liposomes, dendrimers, and polymeric nanoparticles are some of the many nanoparticle formulations that can be used as carriers for targeted drug delivery in cancer treatment. Liposomes are prone to quick elimination from the bloodstream and can release the encapsulated drug prematurely, requiring a modified liposome for long circulation time. Liposomes can be modified into a long-circulating nanoliposome, generated by the addition of polyethylene glycol chains on their surface. Dendrimers are highly branched spherical macromolecules that present an attractive topology for the incorporation of hydrophobic, hydrophilic, and charged drugs in different compartments of the dendrimer structure. Polymeric nanoparticles have an additional advantage over other nanoparticle formulations, as the surface of the particles can be chemically modified according to specific requirements [7, 8]. The surface of nanoparticles can be modified with ligands in order to pursue active targeting to cancer cells. The modifications can occur at the end of the synthesis by coupling ligands using a linker. In the case of nanoparticles, the modifications can also be achieved during polymerization. For instance, certain compounds can be used for other ionic functional groups. Moreover, nanoparticles can be further engineered to enhance cellular uptake. Nanoparticles can be further functionalized with a nuclear localization signal, which dramatically enhances the nuclear uptake of conjugated therapeutics. The obtained nanoparticles were shown to be more efficient than passive targeting, illustrating the potential of the nuclear localization signal in enhancing the efficiency of drug delivery by nanoparticles. Additionally, superparamagnetic nanoparticles have also been used for cancer treatment using an alternative therapy by exposing the particles to an alternating magnetic field. This causes heat generation, which can be used to destroy cancerous tissues or to release the drug formulated in the nanoparticles. Nanoparticles for clinical applications need to possess a high degree of biocompatibility and be stable in biological environments. The safety of the nanoparticle formulations was proven in clinical trials, and these formulations were granted regulatory clearance for human use. Cancer nanomedicines have been tremendously refined, with a variety of nanoparticle formulations having preclinical data and clinical data today. In the past few years, certain formulations have become the largest selling anticancer drugs, and recently a therapy derived from another formulation was shown to improve progression-free survival and established a statistically meaningful increase in overall survival in a clinical trial. However, the application of nanoparticles for drug delivery has emerged as an extensive research area for high-profile commercial investment. Other nanoparticle alternatives include various formulations. Despite the large number of nanomedicines in the pipeline, relatively few nanosized oncology formulations have reached the marketplace. Key challenges to the successful development of improved therapeutic nanoformulations include the complexity of upscaling made difficult by the nanosize of the particle and the hydrophobicity of many anticancer drugs [9, 10].

Clinical Applications and Future Directions

Current Clinical Applications of Nanotechnology in Cancer Treatment

As of early 2021, numerous clinical trials are actively investigating targeted drug delivery by nanotechnology in cancer. They fall into four categories: radiolabeled, antibody-conjugated, liposome-encapsulated nanoparticles, and free nano-doxorubicin. Liposome-encapsulated doxorubicin is clinically active against recurrent and extensive small cell lung cancer, breast cancer, and HIV-associated Kaposi's

sarcoma. Liposomal doxorubicin is the leading third- and later-line treatment against ovarian cancer in platinum-sensitive patients. It shrinks lesions in over fifty percent of cases [11, 12]. Nanoparticles that release free doxorubicin are more effective in inducing a chemotherapy killing response from tumors than traditional drugs, and smaller tumors can be killed using nanoparticles. Nevertheless, clinical responses to nanoparticle-delivered doxorubicin are to date no more than incremental, not the breakthrough needed to impact survival. Newer types of nanoparticles that have been shown to be promising in early animal trials can further improve the chemotherapy dose that solid tumors can sustain. Just as important, low doses of drugs in nanoparticles can be used to simultaneously treat drug-sensitive and drug-insensitive cancers, as well as eliminate the potentially life-threatening side effects of antiangiogenic agents on arterial blood pressure and blood flow that can occur in some cancer patients [13, 14].

Future Directions

Future clinical development should focus on customized chemotherapy designed for each patient's tumor and integrate the best aspects of nanotechnology-based drug delivery. Specifically, to truly tailor and optimize chemotherapy, it is important to also select patients with high tumor uptake of nanoparticles at the specific time at which antiangiogenic therapy is administered. Removing uncertainty about the uptake of the systemically injected nanoparticles by the tumor and nonmalignant organs and tissues in each patient would also enable accurately assessing tissue and organ radiation doses after nanoparticle-uptake-specific pretreatment [15, 16].

Challenges And Ethical Considerations

In order to be useful for cancer treatment, the commercial scale production of uniform sets of nanoparticles that are absolutely reproducible and meet the regulatory compliance on purity is a major task. Gold and stealth or PEG coating, stealth for reduction of reticular endothelial system mediated uptake and PEG for swerving antibody opsonization mediated mononuclear phagocytic system clearance, and simultaneous use of antibody to target tumor markers at the surface, constitute some of the general elements in the design of various nanoparticles. Though this area has seen many advancements since the beginning of research in this field, commercial production for clinical trials and marketable production has to be achieved, with clinical translation being the major obstacle. The biocompatibility and safety of nanoparticles have always been major concerns. Both biocompatible drugs and carriers are desirable for pharmaceutical applications. No information about long-term biocompatibility and metabolism of those nanoparticles has been produced. The in vivo metabolism and potential long-term toxicity are necessary steps before the launch of clinical trials [17, 18]. There are also many ethical considerations that overlap when combining nanotechnology and medicine. It may be difficult for everyone to understand the principles underlying complex new materials and even more complicated when these principles are carried over into the realm of medicine. Though informed consent is a requirement for clinical trials, it is unlikely that the public will be able to fully understand these new materials and vote to accept the associated risks. Even if nano-medicine is significantly better, it could still be a tough decision for some individuals. A balanced approach and dialogue should be undertaken with the general public. A major problem with nano-medicine is the socioeconomic and political complexities, which could result in ongoing neglect and limited access to these types of therapy. Various levels of advice can be beneficial to ethically guide the development of this research. In addition, various elements including structural studies should implicitly support the clinical investigation of nano-material deposition in biological specimens and the development of various guidelines by interdisciplinary panels. Furthermore, nano-toxicologists should also be involved in nano-medicine discussions, with respect to the monitoring of various aspects of human exposure and other risks as well [19, 20].

CONCLUSION

Nanotechnology offers significant advancements in cancer therapy, notably in enhancing targeted drug delivery and minimizing systemic toxicity. Through the unique capabilities of nanoparticles, such as controlled release and active targeting, there is considerable potential to increase drug efficacy and improve patient outcomes. Despite these benefits, challenges in large-scale production, long-term biocompatibility, and ethical transparency remain. Addressing these concerns will be critical for the successful integration of nanomedicine into clinical practice. Continued innovation and research into nanoparticle drug delivery could potentially redefine cancer treatment, offering more effective and personalized therapeutic options.

REFERENCES

1. Ding M, Liu W, Gref R. Nanoscale MOFs: From synthesis to drug delivery and theranostics applications. Advanced Drug Delivery Reviews. 2022 Nov 1;190:114496.

2. Dubey R, Dutta D, Sarkar A, Chattopadhyay P. Functionalized carbon nanotubes: Synthesis, properties and applications in water purification, drug delivery, and material and biomedical sciences. Nanoscale Advances. 2021;3(20):5722-44.
3. Huang D, Sun L, Huang L, Chen Y. Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. Journal of personalized medicine. 2021 Feb 14;11(2):124.
4. Ejigah V, Owoseni O, Bataille-Backer P, Ogundipe OD, Fisusi FA, Adesina SK. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers. 2022 Jun 27;14(13):2601. mdpi.com
5. Rahim MA, Jan N, Khan S, Shah H, Madni A, Khan A, Jabar A, Khan S, Elhissi A, Hussain Z, Aziz HC. Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting. Cancers. 2021 Feb 7;13(4):670. mdpi.com
6. Narum SM, Le T, Le DP, Lee JC, Donahue ND, Yang W, Wilhelm S. Passive targeting in nanomedicine: fundamental concepts, body interactions, and clinical potential. InNanoparticles for biomedical applications 2020 Jan 1 (pp. 37-53). Elsevier. wilhelm-lab.com
7. Singhvi G, Rapalli VK, Nagpal S, Dubey SK, Saha RN. Nanocarriers as potential targeted drug delivery for cancer therapy. Nanoscience in Medicine Vol. 1. 2020:51-88. [HTML]
8. Raj S, Khurana S, Choudhari R, Kesari KK, Kamal MA, Garg N, Ruokolainen J, Das BC, Kumar D. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. InSeminars in cancer biology 2021 Feb 1 (Vol. 69, pp. 166-177). Academic Press. aalto.fi
9. Augustine R, Hasan A, Primavera R, Wilson RJ, Thakor AS, Kevadiya BD. Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components. Materials Today Communications. 2020 Dec 1;25:101692. sciencedirect.com
10. Rosero WA, Barbezan AB, de Souza CD, Rostelato ME. Review of advances in coating and functionalization of gold nanoparticles: from theory to biomedical application. Pharmaceutics. 2024;16(2):255. [HTML]
11. Siafaka P, ğlar EŞ, Gündoğdu EA, tündağ Okur N. New Era on combining both imaging and drug delivery to treat cancer. Current Pharmaceutical Biotechnology. 2023 Jun 1;24(7):832-55. [HTML]
12. Kurmi BD, Patel P, Paliwal R, Paliwal SR. Molecular approaches for targeted drug delivery towards cancer: A concise review with respect to nanotechnology. Journal of drug delivery science and technology. 2020 Jun 1;57:101682. [HTML]
13. Li K, Zhou D, Cui H, Mo G, Liu Y, Zheng K, Zhou Z, Li J, Dai P, Sun J, Zhang Y. Size-transformable gelatin/nanochitosan/doxorubicin nanoparticles with sequentially triggered drug release for anticancer therapy. Colloids and Surfaces B: Biointerfaces. 2022 Dec 1;220:112927. [HTML]\
14. Zang X, Song J, Yi X, Piyu J. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer. Journal of Materials Chemistry B. 2022;10(12):2019-27.
15. Anand U, Dey A, Chandel AK, Sanyal R, Mishra A, Pandey DK, De Falco V, Upadhyay A, Kandimalla R, Chaudhary A, Dhanjal JK. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases. 2023 Jul 1;10(4):1367-401. sciencedirect.com
16. Gu W, Meng F, Haag R, Zhong Z. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. Journal of controlled release. 2021 Jan 10;329:676-95.
17. Ferraris C, Rimicci C, Garelli S, Ugazio E, Battaglia L. Nanosystems in cosmetic products: A brief overview of functional, market, regulatory and safety concerns. Pharmaceutics. 2021 Sep 5;13(9):1408.
18. Papaluca M, Ehmann F, Pita R, Hernan D. Regulatory issues in nanomedicines. Pharmaceutical Nanotechnology: Innovation and Production: Innovation and Production. 2017 Jan 25:497-520.
19. Mehta N, Shetty S, Prajapati BG, Shetty S. Regulatory and ethical concerns in the use of nanomaterials. InAlzheimer's Disease and Advanced Drug Delivery Strategies 2024 Jan 1 (pp. 197-212). Academic Press. [HTML]
20. GadelHak Y, Muhammad A, El-Azazy M, El-Shafie AS, Shibl MF, Mahmoud R. Computer-Aided Design of Large-Scale Nanomaterials Synthesis Processes: A Detailed Review. ChemBioEng Reviews. 2024 Aug;11(4):e202300075.

CITE AS: Winniefred Nankya. (2024). Nanotechnology in Cancer Treatment: Targeted Drug Delivery. Research Output Journal of Public Health and Medicine 4(2):38-42. https://doi.org/10.59298/ROJPHM/2024/423842